Literature DB >> 26910384

The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype.

Marion Cornelissen1, Zelda Euler2, Tom L G M van den Kerkhof1,2, Marit J van Gils1, Brigitte D M Boeser-Nunnink2, Neeltje A Kootstra2, Fokla Zorgdrager1, Hanneke Schuitemaker2, Jan M Prins3, Rogier W Sanders1,4, Antoinette C van der Kuyl1.   

Abstract

The effect of serial HIV-1 infection on the development of the broadly neutralizing antibody (bNAb) response was studied in an individual, H01-10366, with a serial HIV-1 superinfection (SI), hence triple infection, and compared with the bNAb response in three superinfected as well as 11 monoinfected men who have had sex with men (MSM) from Amsterdam, the Netherlands. Neutralization assays measuring heterologous neutralizing antibody (NAb) titers on a panel of six representative viruses from different HIV-1 subtypes were performed on blood serum samples obtained ∼3 years after primary HIV infection (PHI) and longitudinally for H01-10366. A bNAb response was defined as having a geometric mean neutralization titer (the reciprocal serum dilution giving 50% inhibition of virus infection, inhibitory dilution (ID50)) ≥100 and neutralizing >50% of viruses in the panel with an ID50 titer ≥100. H01-10366 quickly developed a potent NAb response against subtype B viruses before subtype B SI, but no broadening of the response occurred after the second subtype B infection or the third infection with CRF01_AE. When comparing H01-10366 with matched monoinfected (N = 11) and superinfected (N = 3) individuals analyzed 3 years after PHI, we found that 5 of the 15 individuals (4/11 monoinfected, 1/4 SI) developed a bNAb response. However, there was no statistically discernible difference between the bNAb response and HIV-1 SI. Thus, HIV-1 SI was not associated with the breadth and potency of the bNAb response in this small group of Dutch MSM with SI that included a triple HIV-1-infected individual.

Entities:  

Keywords:  HIV-1; heterologous; men who have sex with men; neutralizing antibody; superinfection; triple infection

Mesh:

Substances:

Year:  2016        PMID: 26910384     DOI: 10.1089/aid.2015.0324

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Limited anti-HIV neutralizing antibody breadth and potency before and after HIV superinfection in Danish men who have sex with men.

Authors:  Andrew D Redd; Marie Helleberg; Matthew Sievers; Stephen D Schmidt; Nicole A Doria-Rose; Daniel Bruno; Shelby Traeger; Craig Martens; Jannik Fonager; Gitte Kronborg; Zoe Packman; John R Mascola; Stephen F Porcella; Jan Gerstoft; Thomas C Quinn
Journal:  Infect Dis (Lond)       Date:  2018-10-14

2.  Deciphering Multiplicity of HIV-1C Infection: Transmission of Closely Related Multiple Viral Lineages.

Authors:  Vlad Novitsky; Sikhulile Moyo; Rui Wang; Simani Gaseitsiwe; M Essex
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

3.  HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth.

Authors:  Daniel J Sheward; Jinny Marais; Valerie Bekker; Ben Murrell; Kemal Eren; Jinal N Bhiman; Molati Nonyane; Nigel Garrett; Zenda L Woodman; Quarraisha Abdool Karim; Salim S Abdool Karim; Lynn Morris; Penny L Moore; Carolyn Williamson
Journal:  Cell Host Microbe       Date:  2018-09-27       Impact factor: 21.023

4.  Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.

Authors:  Valentine U Chukwuma; Nurgun Kose; D Noah Sather; Gopal Sapparapu; Rachel Falk; Hannah King; Vidisha Singh; Rebecca Lampley; Delphine C Malherbe; Noah T Ditto; Jonathan T Sullivan; Trevor Barnes; Benjamin J Doranz; Celia C Labranche; David C Montefiori; Spyros A Kalams; Nancy L Haigwood; James E Crowe
Journal:  PLoS One       Date:  2018-12-19       Impact factor: 3.240

5.  Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.

Authors:  Tinashe E Nyanhete; Robert J Edwards; Celia C LaBranche; Katayoun Mansouri; Amanda Eaton; S Moses Dennison; Kevin O Saunders; Derrick Goodman; Katarzyna Janowska; Rachel L Spreng; Lu Zhang; Sarah V Mudrak; Thomas J Hope; Bhavna Hora; Todd Bradley; Ivelin S Georgiev; David C Montefiori; Priyamvada Acharya; Georgia D Tomaras
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

6.  HIV-1 infections with multiple founders associate with the development of neutralization breadth.

Authors:  Eric Lewitus; Samantha M Townsley; Yifan Li; Gina C Donofrio; Bethany L Dearlove; Hongjun Bai; Eric Sanders-Buell; Anne Marie O'Sullivan; Meera Bose; Hannah Kibuuka; Lucas Maganga; Sorachai Nitayaphan; Fredrick K Sawe; Leigh Anne Eller; Nelson L Michael; Victoria R Polonis; Julie A Ake; Sandhya Vasan; Merlin L Robb; Sodsai Tovanabutra; Shelly J Krebs; Morgane Rolland
Journal:  PLoS Pathog       Date:  2022-03-18       Impact factor: 6.823

7.  Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies.

Authors:  Teena Mohan; Zachary Berman; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Sci Rep       Date:  2018-05-17       Impact factor: 4.379

Review 8.  Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.

Authors:  Elise Landais; Penny L Moore
Journal:  Retrovirology       Date:  2018-09-05       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.